conventional chemotherapy

ApprovedSmall molecule

SShanghai Jiao Tong University School of Medicine

conventional chemotherapy is one of 186 small molecule programs targeting Gallbladder Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gallbladder CarcinomaActive, not recruiting

MacroglobulinemiaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Gallbladder CarcinomaPhase 2

Active, not recruiting

MacroglobulinemiaApproved

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Ovarian CancerPhase 2/Phase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

conventional chemotherapy

SShanghai Jiao Tong University School of Medicine

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Halaven

Eisai

Preclinical

38 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

MS Contin

Merck & Co.

Preclinical

2 6

Lexiscan

Astellas

Preclinical

1 7

Adenocard

Astellas

Preclinical

1 8

Blenoxane

Bristol-Myers Squibb

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 10

Effexor

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Impact Of Intermittent And Water-Only Fasting On Gene Expression And Tumor Markers In Breast Cancer

Active, not recruiting·KKhyber Medical University Peshawar·N/A·NCT07440784·60 enrolled

Acute Myeloid Leukemia1 trial

A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

Completed·AAcute Leukemia French Association·Phase 3·NCT00927498·280 enrolled

Gallbladder Carcinoma1 trial

Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03768375·150 enrolled

Macroglobulinemia1 trial

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02844361·70 enrolled

Nasopharyngeal Carcinoma1 trial

Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 3·NCT02944708·384 enrolled

1 more indication

Ovarian Cancer1 trial

Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)

Unknown status·—·Phase 2/3·NCT04055038·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for conventional chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — conventional chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for conventional chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShanghai Jiao Tong University School of Medicine

conventional chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Acute Myeloid Leukemia1 trial

Gallbladder Carcinoma1 trial

Macroglobulinemia1 trial

Nasopharyngeal Carcinoma1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News